Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:advocated_for |
gptkb:scientists
research institutions biotech startups |
| gptkbp:allows |
gene insertions
gene knockouts targeted mutations |
| gptkbp:applies_to |
gptkb:Biology
gptkb:animals gptkb:humans plants |
| gptkbp:based_on |
gptkb:CRISPR_technology
|
| gptkbp:benefits |
efficiency
precision cost-effectiveness |
| gptkbp:can_be_used_to |
treat genetic disorders
create animal models modify crops |
| gptkbp:developed_by |
gptkb:Emmanuelle_Charpentier
gptkb:Jennifer_Doudna |
| gptkbp:has_applications_in |
gptkb:biotechnology
gptkb:Medicine agriculture |
| gptkbp:has_limitations |
regulatory hurdles
delivery methods targeting specificity |
| https://www.w3.org/2000/01/rdf-schema#label |
CRISPR-Cas9 gene editing
|
| gptkbp:investment |
ethical concerns
off-target effects germline editing issues |
| gptkbp:is_associated_with |
HIV research
cancer research agricultural improvements |
| gptkbp:is_challenged_by |
ethical debates
alternative gene editing technologies public opinion concerns |
| gptkbp:is_criticized_for |
impact on biodiversity
potential misuse lack of long-term studies |
| gptkbp:is_explored_in |
gptkb:gene_therapy
agricultural biotechnology pharmaceutical development |
| gptkbp:is_part_of |
gptkb:biotechnology
molecular biology genomics |
| gptkbp:is_regulated_by |
government agencies
bioethics committees |
| gptkbp:is_supported_by |
gptkb:scientific_community
biotechnology companies |
| gptkbp:is_used_in |
research studies
clinical trials |
| gptkbp:used_in |
genetic engineering
genome editing |
| gptkbp:bfsParent |
gptkb:Emmanuelle_Charpentier
|
| gptkbp:bfsLayer |
3
|